Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate at Investor Conferences in March
February 27, 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
44th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27,...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
February 15, 2024 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita...
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
February 08, 2024 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
February 06, 2024 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced data demonstrating treatment with UX111 (ABO-102) AAV gene therapy resulted in rapid...
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
February 05, 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected in first half of 2024 NOVATO, Calif., Feb. 05, 2024...
Ultragenyx anuncia la aprobación de Dojolvi® (triheptanoína) para su inclusión en el Compendio Nacional de Insumos para la Salud de México en el tratamiento de los trastornos de oxidación de ácidos grasos de cadena larga (LC-FAOD)
January 31, 2024 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc, compañía biofarmacéutica dedicada al desarrollo y comercialización de tratamientos novedosos para enfermedades...
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
January 25, 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 (GLOBE...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...